Abstract
Psoriasis remains one of the commonest conditions seen in dermatological practice, and its treatment is one of the greatest cost burdens for the UK National Health Service. Treatment of psoriasis is complex, with numerous overlapping lines and therapies used in combination. This complexity reflects the underlying pathophysiology of the disease as well as the heterogeneous population that it affects. National Institute for Health and Care Excellence (NICE) guidance for the treatment of psoriasis has been available since 2013, and has been the subject of three national audits conducted by the British Association of Dermatologists. This report synthesizes the results of the most recent of those exercises and places it in the context of the NICE guidance and previous audits. It clearly shows the significant burden of disease, issues with provision of services and long waiting times and the marked shift in therapies towards targeted biologic therapies.
Highlights
IntroductionPsoriasis continues to be one of the most common diseases seen in hospital dermatology practice in the United Kingdom[1]
National Institute for Health and Care Excellence (NICE) guidance for the treatment of psoriasis has been available since 2013 and has been the subject of 3 national audits conducted by the British Association of Dermatologists (BAD)
Psoriasis continues to be one of the most common diseases seen in hospital dermatology practice in the United Kingdom[1]
Summary
Psoriasis continues to be one of the most common diseases seen in hospital dermatology practice in the United Kingdom[1]. 2011 saw the publication of the British Association of Dermatologists (BAD) initiated Quality Standards for Dermatology[8] which defines the expected provision of skin care services in the UK. In 2013 the National Institute for Health and Care Excellence (NICE) published standards and guidance for the treatment of psoriasis (CG153)[3]. Following this, the BAD conducted an audit of the provision of psoriasis therapy in UK and Irish hospitals[4]. In 2017/2018 a further national audit was conducted across the UK and Ireland to assess the uptake of CG153’s recommendations and standards and assess the adherence to the Quality Standards for Dermatology.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
